Relay Therapeutics, Inc. (RLAY) Stock
1 member of Congress disclosed 1 trade in RLAY since 2023: 0 purchases and 1 sale, most recently Daniel Goldman (sale, Jul 12, 2023). 5 of the hedge funds AlphaScala tracks reported RLAY in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $11.07M. Company insiders reported 0 open-market buys and 13 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which members of Congress traded Relay Therapeutics, Inc. (RLAY)?
Most recent: Daniel Goldman (sale, Jul 12, 2023); records start Jul 12, 2023.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Dan Goldman D-NY · House | 2023-07-12 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 20, 2026.
See all RLAY political trades →Which hedge funds own RLAY?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 592K | $11.07M | +70% |
| Citadel Ken Griffin | 474K | $8.86M | +169% |
| Duquesne Family Office Stanley Druckenmiller | 349K | $6.53M | NEW |
| Renaissance Technologies Jim Simons (founder) | 192K | $3.60M | -71% |
| Marshall Wace | 18K | $333.8K | -98% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Relay Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 7, 26 | Patel Sanjiv | President and CEO | SELL | 48.2K | $872K |
| Oct 6, 26 | Catinazzo Thomas | Chief Financial Officer | SELL | 17.5K | $325K |
| Oct 6, 26 | Catinazzo Thomas | Chief Financial Officer | SELL | 206 | $4K |
| Sep 8, 26 | Patel Sanjiv | President and CEO | SELL | 48.2K | $913K |
| Sep 8, 26 | Catinazzo Thomas | Chief Financial Officer | SELL | 17.7K | $336K |
| Sep 8, 26 | Bergstrom Donald A | President, R&D | SELL | 8.5K | $162K |
| Aug 26, 26 | Rahmer Peter | See remarks | SELL | 4.5K | $90K |
| Aug 25, 26 | Svf Pauling (Cayman) Ltd | 10%+ Owner | SELL | 6.00M | $116.4M |
| Aug 17, 26 | Patel Sanjiv | President and CEO | SELL | 48.2K | $980K |
| Aug 14, 26 | Catinazzo Thomas | Chief Financial Officer | SELL | 17.7K | $350K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →RLAY price chart
Powered by TradingViewWhat does Relay Therapeutics, Inc. do?
Relay Therapeutics Inc. is a clinical-stage precision medicine company focused on transforming drug discovery through its proprietary Dynamo platform, which integrates computational modeling, machine learning, and experimental approaches to target dynamic protein motions for small molecule therapeutics. The company specializes in oncology and genetic diseases, with its lead candidate RLY-2608 (zovegalisib), a pan-mutant and isoform-selective PI3Kα inhibitor in clinical development for PI3Kα-mutated HR+/HER2- metastatic breast cancer, solid tumors, and vascular malformations, often in combination with fulvestrant or CDK4/6 inhibitors. Additional programs include an αGal chaperone for Fabry disease, RLY-8161 targeting NRAS-driven tumors, and RLY-1013 as an estrogen receptor alpha degrader. Relay Therapeutics Inc. maintains collaborations with partners like D. E. Shaw Research for computational target analysis, Elevar Therapeutics for lirafugratinib (RLY-4008) in FGFR2-driven cancers, and Pfizer for combination therapies. Founded in 2015 and headquartered in Cambridge, Massachusetts, it plays a key role in advancing precision oncology by addressing challenging protein targets to develop potentially transformative treatments.